{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:19:17Z","timestamp":1792783157418,"version":"4.5.0"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universitat Aut\u00f2noma de Barcelona","id":[{"id":"https:\/\/ror.org\/052g8jq94","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasing global health challenge closely linked to obesity and the metabolic syndrome. This review explores the role of aldosterone as a central contributor to metabolic dysfunction, highlighting its association with adipose tissue dysfunction and systemic insulin resistance which can further influence MASLD development and progression. While aldosterone-related organ damage has been extensively studied in other contexts such as kidney disease, its involvement in MASLD has received less attention. Beyond classical renin-angiotensin-aldosterone system activation, aldosterone secretion can be directly stimulated by leptin and other adipogenic factors, creating a pathogenic link between obesity and metabolic impairment. Aldosterone amplifies chronic inflammation, oxidative stress and insulin resistance, primarily through mineralocorticoid receptor (MR)-dependent mechanisms. These involve both genomic actions regulating pro-inflammatory genes and rapid non-genomic signalling. Additionally, aldosterone MR-independent effects, can further contribute to oxidative stress and inflammatory responses. Significantly, the MR is expressed in liver cells, including hepatocytes, liver sinusoidal endothelial cells, Kupffer cells, and hepatic stellate cells. This expression can allow for direct aldosterone-mediated effect on hepatic inflammation, oxidative stress, and fibrosis, which can occur alongside or independently of systemic metabolic pathways. Such direct mechanisms may explain associations found in clinical studies correlating high aldosterone levels -even with low renin- with the prevalence and progression of MASLD. Recognizing aldosterone as a pleiotropic hormone that integrates metabolic and hepatic disease offers new insights into the cardio-kidney-metabolic syndrome and underscores the potential for targeted therapies.<\/jats:p>","DOI":"10.1007\/s11154-026-10056-3","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T03:02:11Z","timestamp":1782788531000},"page":"943-958","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Unveiling the role of aldosterone in metabolic dysfunction\u2013associated steatotic liver disease"],"prefix":"10.1007","volume":"27","author":[{"given":"Anna","family":"Hern\u00e1ndez-Rubio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Teresa","family":"Juli\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Valassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manel","family":"Puig-Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"issue":"1","key":"10056_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41572-025-00599-1","volume":"11","author":"DQ Huang","year":"2025","unstructured":"Huang DQ, Wong VWS, Rinella ME, Boursier J, Lazarus JV, Yki-J\u00e4rvinen H, et al. Metabolic dysfunction-associated steatotic liver disease in adults. Nat Rev Dis Prim. 2025;11(1):14.","journal-title":"Nat Rev Dis Prim"},{"issue":"10464","key":"10056_CR2","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/S0140-6736(24)01811-7","volume":"404","author":"M Israelsen","year":"2024","unstructured":"Israelsen M, Francque S, Tsochatzis EA, Krag A. Steatotic liver disease. Lancet (London England). 2024;404(10464):1761\u201378.","journal-title":"Lancet (London England)"},{"issue":"5","key":"10056_CR3","doi-asserted-by":"publisher","first-page":"C1637","DOI":"10.1152\/ajpcell.00951.2024","volume":"328","author":"MS Kuchay","year":"2025","unstructured":"Kuchay MS, Choudhary NS, Ramos-Molina B. Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease. Am J Physiol Cell Physiol. 2025;328(5):C1637\u201366.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"7","key":"10056_CR4","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMra2412865","volume":"393","author":"G Targher","year":"2025","unstructured":"Targher G, Valenti L, Byrne CD. Metabolic Dysfunction-Associated Steatotic Liver Disease. N Engl J Med. 2025;393(7):683\u201398.","journal-title":"N Engl J Med"},{"key":"10056_CR5","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3389\/fphar.2020.00432","volume":"11","author":"M Yang","year":"2020","unstructured":"Yang M, Ma X, Xuan X, Deng H, Chen Q, Yuan L. Liraglutide Attenuates Non-Alcoholic Fatty Liver Disease in Mice by Regulating the Local Renin-Angiotensin System. Front Pharmacol. 2020;11:432.","journal-title":"Front Pharmacol"},{"issue":"9","key":"10056_CR6","first-page":"BR248","volume":"17","author":"P Lu","year":"2011","unstructured":"Lu P, Liu H, Yin H, Yang L. Expression of angiotensinogen during hepatic fibrogenesis and its effect on hepatic stellate cells. Med Sci Monit Int Med J Exp Clin Res. 2011;17(9):BR248\u201356.","journal-title":"Med Sci Monit Int Med J Exp Clin Res"},{"issue":"17","key":"10056_CR7","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.1113\/JP277994","volume":"597","author":"C Hurr","year":"2019","unstructured":"Hurr C, Simonyan H, Morgan DA, Rahmouni K, Young CN. Liver sympathetic denervation reverses obesity-induced hepatic steatosis. J Physiol. 2019;597(17):4565\u201380.","journal-title":"J Physiol"},{"key":"10056_CR8","doi-asserted-by":"crossref","unstructured":"Carnagarin R, Tan K, Adams L, Matthews VB, Kiuchi MG, Marisol Lugo Gavidia L et al. Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-A Condition Associated with Heightened Sympathetic Activation. Int J Mol Sci. 2021;22(8).","DOI":"10.3390\/ijms22084241"},{"issue":"10","key":"10056_CR9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jchf.2022.06.005","volume":"10","author":"T Kahlon","year":"2022","unstructured":"Kahlon T, Carlisle S, Otero Mostacero D, Williams N, Trainor P, DeFilippis AP, Angiotensinogen. More Than its Downstream Products: Evidence From Population Studies and Novel Therapeutics. JACC Heart Fail. 2022;10(10):699\u2013713.","journal-title":"JACC Heart Fail"},{"key":"10056_CR10","doi-asserted-by":"crossref","unstructured":"Kanbay M, Guldan M, Ozbek L, Al-Shiab R, Laffin LJ. Dallas, Tex. Angiotensinogen Reconsidered: Evolving Perspectives in Hypertension Research. Hypertens (1979). 2026.","DOI":"10.1161\/HYPERTENSIONAHA.125.26091"},{"key":"10056_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.peptides.2014.10.005","volume":"62","author":"S Moreira de Mac\u00eado","year":"2014","unstructured":"Moreira de Mac\u00eado S, Guimar\u00e3es TA, Feltenberger JD, Sousa Santos SH. The role of renin-angiotensin system modulation on treatment and prevention of liver diseases. Peptides. 2014;62:189\u201396.","journal-title":"Peptides"},{"issue":"10","key":"10056_CR12","first-page":"1525","volume":"36","author":"Y Wu","year":"2016","unstructured":"Wu Y, Ma KL, Zhang Y, Wen Y, Wang GH, Hu ZB, et al. Lipid disorder and intrahepatic renin-angiotensin system activation synergistically contribute to non-alcoholic fatty liver disease. Liver Int Off J Int Assoc Study Liver. 2016;36(10):1525\u201334.","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"10056_CR13","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ijcard.2016.09.035","volume":"224","author":"X Lai","year":"2016","unstructured":"Lai X, Yang L, L\u00e9gar\u00e9 S, Angileri F, Chen X, Fang Q, et al. Dose-response relationship between serum uric acid levels and risk of incident coronary heart disease in the Dongfeng-Tongji Cohort. Int J Cardiol. 2016;224:299\u2013304.","journal-title":"Int J Cardiol"},{"key":"10056_CR14","doi-asserted-by":"crossref","unstructured":"McGrath MS, Wentworth BJ. The Renin-Angiotensin System in Liver Disease. Int J Mol Sci. 2024;25(11).","DOI":"10.3390\/ijms25115807"},{"issue":"3","key":"10056_CR15","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/j.2040-4603.2014.tb00565.x","volume":"4","author":"WB Bollag","year":"2014","unstructured":"Bollag WB. Regulation of aldosterone synthesis and secretion. Compr Physiol. 2014;4(3):1017\u201355.","journal-title":"Compr Physiol"},{"issue":"3","key":"10056_CR16","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1210\/er.2005-0004","volume":"26","author":"JW Funder","year":"2005","unstructured":"Funder JW. The nongenomic actions of aldosterone. Endocr Rev. 2005;26(3):313\u201321.","journal-title":"Endocr Rev"},{"issue":"13","key":"10056_CR17","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1161\/CIRCULATIONAHA.124.073507","volume":"152","author":"R Goupil","year":"2025","unstructured":"Goupil R, Desbiens L-C, Merabtine A, Agharazii M, Madore F, Vaidya A, et al. Subclinical Primary Aldosteronism and Major Adverse Cardiovascular Events: A Longitudinal Population-Based Cohort Study. Circulation. 2025;152(13):913\u201323.","journal-title":"Circulation"},{"issue":"14","key":"10056_CR18","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","volume":"393","author":"JM Flack","year":"2025","unstructured":"Flack JM, Azizi M, Brown JM, Dwyer JP, Fronczek J, Jones ESW, et al. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. N Engl J Med. 2025;393(14):1363\u201374.","journal-title":"N Engl J Med"},{"issue":"5","key":"10056_CR19","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.jacc.2025.06.012","volume":"86","author":"F Fioretti","year":"2025","unstructured":"Fioretti F, Testani JM, Tio MC, Pitt B, Butler J. Aldosterone and Aldosterone Modulation in Cardio-Kidney Diseases. J Am Coll Cardiol. 2025;86(5):354\u201373.","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"10056_CR20","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023;148(20):1606\u201335.","journal-title":"Circulation"},{"key":"10056_CR21","doi-asserted-by":"crossref","unstructured":"Bochud M, Nussberger J, Bovet P, Maillard MR, Elston RC, Paccaud F et al. Dallas, Tex. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertens (1979). 2006;48(2):239\u201345.","DOI":"10.1161\/01.HYP.0000231338.41548.fc"},{"issue":"1","key":"10056_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.diabet.2019.02.003","volume":"46","author":"C Bothou","year":"2020","unstructured":"Bothou C, Beuschlein F, Spyroglou A. Links between aldosterone excess and metabolic complications: A comprehensive review. Diabetes Metab. 2020;46(1):1\u20137.","journal-title":"Diabetes Metab"},{"issue":"1","key":"10056_CR23","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S2468-1253(24)00310-8","volume":"10","author":"JJ Gries","year":"2025","unstructured":"Gries JJ, Lazarus JV, Brennan PN, Siddiqui MS, Targher G, Lang CC, et al. Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease. lancet Gastroenterol Hepatol. 2025;10(1):82\u201394.","journal-title":"lancet Gastroenterol Hepatol"},{"issue":"6","key":"10056_CR24","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/jgh.14961","volume":"35","author":"Y Li","year":"2020","unstructured":"Li Y, Zhang Y, Chen T, Huang Y, Zhang Y, Geng S, et al. Role of aldosterone in the activation of primary mice hepatic stellate cell and liver fibrosis via NLRP3 inflammasome. J Gastroenterol Hepatol. 2020;35(6):1069\u201377.","journal-title":"J Gastroenterol Hepatol"},{"issue":"8","key":"10056_CR25","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1007\/s00204-025-04075-3","volume":"99","author":"X Kuang","year":"2025","unstructured":"Kuang X, Naiki-Ito A, Kawamura H, Murakami A, Komura M, Kato H, et al. Hepatic stellate cell inhibition by angiotensin II receptor blocker mitigates liver injury and fibrosis via NF-\u03baB-galectin-3 suppression in a rat nonalcoholic steatohepatitis model. Arch Toxicol. 2025;99(8):3393\u2013412.","journal-title":"Arch Toxicol"},{"issue":"4","key":"10056_CR26","doi-asserted-by":"publisher","first-page":"G446","DOI":"10.1152\/ajpgi.00238.2021","volume":"322","author":"Z Huang","year":"2022","unstructured":"Huang Z, Khalifa MO, Li P, Huang Y, Gu W, Li T-S. Angiotensin receptor blocker alleviates liver fibrosis by altering the mechanotransduction properties of hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol. 2022;322(4):G446\u201356.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"1","key":"10056_CR27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10741-016-9591-2","volume":"22","author":"MM Hermidorff","year":"2017","unstructured":"Hermidorff MM, de Assis LVM, Isoldi MC. Genomic and rapid effects of aldosterone: what we know and do not know thus far. Heart Fail Rev. 2017;22(1):65\u201389.","journal-title":"Heart Fail Rev"},{"issue":"2","key":"10056_CR28","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.mce.2011.07.019","volume":"350","author":"R Dooley","year":"2012","unstructured":"Dooley R, Harvey BJ, Thomas W. Non-genomic actions of aldosterone: from receptors and signals to membrane targets. Mol Cell Endocrinol. 2012;350(2):223\u201334.","journal-title":"Mol Cell Endocrinol"},{"issue":"22","key":"10056_CR29","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1161\/CIRCULATIONAHA.115.018226","volume":"132","author":"A-C Huby","year":"2015","unstructured":"Huby A-C, Antonova G, Groenendyk J, Gomez-Sanchez CE, Bollag WB, Filosa JA, et al. Adipocyte-Derived Hormone Leptin Is a Direct Regulator of Aldosterone Secretion, Which Promotes Endothelial Dysfunction and Cardiac Fibrosis. Circulation. 2015;132(22):2134\u201345.","journal-title":"Circulation"},{"issue":"2","key":"10056_CR30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/MNH.0000000000000384","volume":"27","author":"JL Faulkner","year":"2018","unstructured":"Faulkner JL, Bruder-Nascimento T, Belin de Chantem\u00e8le EJ. The regulation of aldosterone secretion by leptin: implications in obesity-related cardiovascular disease. Curr Opin Nephrol Hypertens. 2018;27(2):63\u20139.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"1\u20132","key":"10056_CR31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.mce.2012.03.005","volume":"378","author":"F Jing","year":"2013","unstructured":"Jing F, Mogi M, Horiuchi M. Role of renin-angiotensin-aldosterone system in adipose tissue dysfunction. Mol Cell Endocrinol. 2013;378(1\u20132):23\u20138.","journal-title":"Mol Cell Endocrinol"},{"key":"10056_CR32","doi-asserted-by":"crossref","unstructured":"Briones AM, Nguyen Dinh Cat A, Callera GE, Yogi A, Burger D, He Y et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertens (Dallas, Tex 1979). 2012;59(5):1069\u201378.","DOI":"10.1161\/HYPERTENSIONAHA.111.190223"},{"issue":"1","key":"10056_CR33","doi-asserted-by":"publisher","first-page":"F7","DOI":"10.1530\/JME-16-0025","volume":"57","author":"AN Dinh Cat","year":"2016","unstructured":"Dinh Cat AN, Friederich-Persson M, White A, Touyz RM. Adipocytes, aldosterone and obesity-related hypertension. J Mol Endocrinol. 2016;57(1):F7\u201321.","journal-title":"J Mol Endocrinol"},{"issue":"4","key":"10056_CR34","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1081\/ERC-200044122","volume":"30","author":"M Ehrhart-Bornstein","year":"2004","unstructured":"Ehrhart-Bornstein M, Arakelyan K, Krug AW, Scherbaum WA, Bornstein SR. Fat cells may be the obesity-hypertension link: human adipogenic factors stimulate aldosterone secretion from adrenocortical cells. Endocr Res. 2004;30(4):865\u201370.","journal-title":"Endocr Res"},{"issue":"5","key":"10056_CR35","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1161\/HYPERTENSIONAHA.115.06642","volume":"67","author":"A-C Huby","year":"2016","unstructured":"Huby A-C, Otvos LJ, Belin de Chantem\u00e8le EJ. Leptin Induces Hypertension and Endothelial Dysfunction via Aldosterone-Dependent Mechanisms in Obese Female Mice. Hypertens (Dallas Tex 1979). 2016;67(5):1020\u20138.","journal-title":"Hypertens (Dallas Tex 1979)"},{"key":"10056_CR36","doi-asserted-by":"publisher","first-page":"111836","DOI":"10.1016\/j.mce.2022.111836","volume":"561","author":"G Ling","year":"2023","unstructured":"Ling G, Bruno J, Albert SG, Dhindsa S. Fatty acids as a direct regulator of aldosterone hypersecretion. Mol Cell Endocrinol. 2023;561:111836.","journal-title":"Mol Cell Endocrinol"},{"key":"10056_CR37","doi-asserted-by":"publisher","first-page":"745045","DOI":"10.3389\/fendo.2021.745045","volume":"12","author":"M Berney","year":"2021","unstructured":"Berney M, Vakilzadeh N, Maillard M, Faouzi M, Grouzmann E, Bonny O, et al. Bariatric Surgery Induces a Differential Effect on Plasma Aldosterone in Comparison to Dietary Advice Alone. Front Endocrinol (Lausanne). 2021;12:745045.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"10056_CR38","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/hr.2013.45","volume":"36","author":"JN Cooper","year":"2013","unstructured":"Cooper JN, Fried L, Tepper P, Barinas-Mitchell E, Conroy MB, Evans RW, et al. Changes in serum aldosterone are associated with changes in obesity-related factors in normotensive overweight and obese young adults. Hypertens Res. 2013;36(10):895\u2013901.","journal-title":"Hypertens Res"},{"key":"10056_CR39","doi-asserted-by":"crossref","unstructured":"Oliveras A, Galceran I, Goday A, V\u00e1zquez S, Sans L, Riera M et al. Improvement of Arterial Stiffness One Month after Bariatric Surgery and Potential Mechanisms. J Clin Med. 2021;10(4).","DOI":"10.3390\/jcm10040691"},{"issue":"1","key":"10056_CR40","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/jch.14129","volume":"23","author":"A Oliveras","year":"2021","unstructured":"Oliveras A, Molina L, Goday A, Sans L, Riera M, Vazquez S, et al. Effect of bariatric surgery on cardiac structure and function in obese patients: Role of the renin-angiotensin system. J Clin Hypertens (Greenwich). 2021;23(1):181\u201392.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"5","key":"10056_CR41","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1038\/s41440-023-01170-9","volume":"46","author":"T Haze","year":"2023","unstructured":"Haze T, Ozawa M, Kawano R, Haruna A, Ohki Y, Suzuki S, et al. Effect of the interaction between the visceral-to-subcutaneous fat ratio and aldosterone on cardiac function in patients with primary aldosteronism. Hypertens Res. 2023;46(5):1132\u201344.","journal-title":"Hypertens Res"},{"issue":"11","key":"10056_CR42","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1161\/HYPERTENSIONAHA.125.24995","volume":"82","author":"H Shen","year":"2025","unstructured":"Shen H, Wu Z, Luo W, Chen X, Yang J, Zeng Q, et al. Perirenal Adipose Tissue and Hypertension: Observational and Genetic Analyses. Hypertens (Dallas Tex 1979). 2025;82(11):1809\u201321.","journal-title":"Hypertens (Dallas Tex 1979)"},{"issue":"12","key":"10056_CR43","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1038\/s41440-025-02401-x","volume":"48","author":"R Mitsuno","year":"2025","unstructured":"Mitsuno R, Nakamura T, Nakamura K, Kaneko K, Kojima D, Mizutani Y, et al. Effects of perirenal fat accumulation on cardiometabolic and renal functions and mineralocorticoid receptor activation in primary aldosteronism. Hypertens Res. 2025;48(12):3244\u201356.","journal-title":"Hypertens Res"},{"issue":"4","key":"10056_CR44","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/ejendo\/lvaf190","volume":"193","author":"S Kloock","year":"2025","unstructured":"Kloock S, Kagan L, Ziegler C, Srivastava M, T\u00f6njes A, Rayes N, et al. Adipose tissue signaling in aldosterone-producing adenomas: paracrine and endocrine effects. Eur J Endocrinol. 2025;193(4):440\u201352.","journal-title":"Eur J Endocrinol"},{"key":"10056_CR45","doi-asserted-by":"publisher","unstructured":"Costa R, Rodrigues D, Gon\u00e7alves T, Alves J, Awata W, Bruder-Nascimento A et al. Autophagy induction protects the perivascular adipose tissue during hyperaldosteronism-induced hypertension. Physiology [Internet]. 2023;38(S1):5734527. Available from: https:\/\/doi.org\/10.1152\/physiol.2023.38.S1.5734527","DOI":"10.1152\/physiol.2023.38.S1.5734527"},{"key":"10056_CR46","doi-asserted-by":"publisher","unstructured":"Costa RM, Bruder-Nascimento A, Alves JV, Awata WMC, Singh S, Rodrigues D et al. Beclin-1-dependent autophagy protects perivascular adipose tissue function from hyperaldosteronism effects. Am J Physiol Circ Physiol. 2025;328(6):H1253\u201366. https:\/\/doi.org\/10.1152\/ajpheart.00829.2024","DOI":"10.1152\/ajpheart.00829.2024"},{"key":"10056_CR47","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.steroids.2014.08.016","volume":"91","author":"JM Luther","year":"2014","unstructured":"Luther JM. Effects of aldosterone on insulin sensitivity and secretion. Steroids. 2014;91:54\u201360.","journal-title":"Steroids"},{"issue":"1\u20132","key":"10056_CR48","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s11010-012-1452-2","volume":"372","author":"J Selvaraj","year":"2013","unstructured":"Selvaraj J, Sathish S, Mayilvanan C, Balasubramanian K. Excess aldosterone-induced changes in insulin signaling molecules and glucose oxidation in gastrocnemius muscle of adult male rat. Mol Cell Biochem. 2013;372(1\u20132):113\u201326.","journal-title":"Mol Cell Biochem"},{"issue":"4","key":"10056_CR49","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1210\/en.2008-1018","volume":"150","author":"T Wada","year":"2009","unstructured":"Wada T, Ohshima S, Fujisawa E, Koya D, Tsuneki H, Sasaoka T. Aldosterone inhibits insulin-induced glucose uptake by degradation of insulin receptor substrate (IRS) 1 and IRS2 via a reactive oxygen species-mediated pathway in 3T3-L1 adipocytes. Endocrinology. 2009;150(4):1662\u20139.","journal-title":"Endocrinology"},{"issue":"1\u20132","key":"10056_CR50","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cca.2009.06.030","volume":"407","author":"J Selvaraj","year":"2009","unstructured":"Selvaraj J, Muthusamy T, Srinivasan C, Balasubramanian K. Impact of excess aldosterone on glucose homeostasis in adult male rat. Clin Chim Acta. 2009;407(1\u20132):51\u20137.","journal-title":"Clin Chim Acta"},{"issue":"2","key":"10056_CR51","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1507\/endocrj.51.243","volume":"51","author":"R Yamashita","year":"2004","unstructured":"Yamashita R, Kikuchi T, Mori Y, Aoki K, Kaburagi Y, Yasuda K, et al. Aldosterone stimulates gene expression of hepatic gluconeogenic enzymes through the glucocorticoid receptor in a manner independent of the protein kinase B cascade. Endocr J. 2004;51(2):243\u201351.","journal-title":"Endocr J"},{"issue":"2","key":"10056_CR52","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2337\/db12-0905","volume":"62","author":"SB Bender","year":"2013","unstructured":"Bender SB, McGraw AP, Jaffe IZ, Sowers JR. Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease? Diabetes. 2013;62(2):313\u20139.","journal-title":"Diabetes"},{"issue":"3","key":"10056_CR53","doi-asserted-by":"publisher","first-page":"R276","DOI":"10.1152\/ajpregu.00280.2020","volume":"320","author":"G Jia","year":"2021","unstructured":"Jia G, Lockette W, Sowers JR. Mineralocorticoid receptors in the pathogenesis of insulin resistance and related disorders: from basic studies to clinical disease. Am J Physiol Regul Integr Comp Physiol. 2021;320(3):R276\u201386.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"8","key":"10056_CR54","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1007\/s00125-011-2158-9","volume":"54","author":"JM Luther","year":"2011","unstructured":"Luther JM, Luo P, Kreger MT, Brissova M, Dai C, Whitfield TT, et al. Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets. Diabetologia. 2011;54(8):2152\u201363.","journal-title":"Diabetologia"},{"issue":"1","key":"10056_CR55","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/HJH.0b013e3280108e6f","volume":"25","author":"G Giacchetti","year":"2007","unstructured":"Giacchetti G, Ronconi V, Turchi F, Agostinelli L, Mantero F, Rilli S, et al. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens. 2007;25(1):177\u201386.","journal-title":"J Hypertens"},{"issue":"9","key":"10056_CR56","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1210\/jc.2006-0736","volume":"91","author":"C Catena","year":"2006","unstructured":"Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi G, Novello M, et al. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab. 2006;91(9):3457\u201363.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10056_CR57","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1161\/HYPERTENSIONAHA.111.180521","volume":"58","author":"E Kumagai","year":"2011","unstructured":"Kumagai E, Adachi H, Jacobs DRJ, Hirai Y, Enomoto M, Fukami A, et al. Plasma aldosterone levels and development of insulin resistance: prospective study in a general population. Hypertens (Dallas Tex 1979). 2011;58(6):1043\u20138.","journal-title":"Hypertens (Dallas Tex 1979)"},{"issue":"1","key":"10056_CR58","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41581-021-00490-8","volume":"18","author":"J Barrera-Chimal","year":"2022","unstructured":"Barrera-Chimal J, Lima-Posada I, Bakris GL, Jaisser F. Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects. Nat Rev Nephrol. 2022;18(1):56\u201370.","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"10056_CR59","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1210\/clinem\/dgae396","volume":"110","author":"D Nedungadi","year":"2024","unstructured":"Nedungadi D, Ayodele Adesanya TM, Rayan MN, Zhao S, Williams A, Brock G, et al. The Association of Adiposity and RAAS With Incident Diabetes in African Americans: The Jackson Heart Study. J Clin Endocrinol Metab. 2024;110(1):151\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"10056_CR60","doi-asserted-by":"crossref","unstructured":"Hu Y, Zhang J, Liu W, Su X. Determining the Prevalence of Primary Aldosteronism in Patients With New-Onset Type 2 Diabetes and Hypertension. J Clin Endocrinol Metab. 2020;105(4).","DOI":"10.1210\/clinem\/dgz293"},{"key":"10056_CR61","first-page":"e935615","volume":"28","author":"M Higa","year":"2022","unstructured":"Higa M, Ichijo T, Hirose T. Aldosterone-to-Renin Ratio Is Associated with Diabetic Nephropathy in Type 2 Diabetic Patients: A Single-Center Retrospective Study. Med Sci Monit Int Med J Exp Clin Res. 2022;28:e935615.","journal-title":"Med Sci Monit Int Med J Exp Clin Res"},{"key":"10056_CR62","doi-asserted-by":"publisher","first-page":"4128174","DOI":"10.1155\/2018\/4128174","volume":"2018","author":"M Hannich","year":"2018","unstructured":"Hannich M, Wallaschofski H, Nauck M, Reincke M, Adolf C, V\u00f6lzke H, et al. Physiological Aldosterone Concentrations Are Associated with Alterations of Lipid Metabolism: Observations from the General Population. Int J Endocrinol. 2018;2018:4128174.","journal-title":"Int J Endocrinol"},{"issue":"1","key":"10056_CR63","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/jch.14607","volume":"25","author":"Q-G Zhu","year":"2023","unstructured":"Zhu Q-G, Zhu F. Meta-analysis of blood parameters related to lipid and glucose metabolism between two subtypes of primary aldosteronism. J Clin Hypertens (Greenwich). 2023;25(1):13\u201321.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10056_CR64","doi-asserted-by":"crossref","unstructured":"Baudrand R, Gupta N, Garza AE, Vaidya A, Leopold JA, Hopkins PN et al. Caveolin 1 Modulates Aldosterone-Mediated Pathways of Glucose and Lipid Homeostasis. J Am Heart Assoc. 2016;5(10).","DOI":"10.1161\/JAHA.116.003845"},{"key":"10056_CR65","doi-asserted-by":"crossref","unstructured":"Otsuka H, Abe M, Kobayashi H. The Effect of Aldosterone on Cardiorenal and Metabolic Systems. Int J Mol Sci. 2023;24(6).","DOI":"10.3390\/ijms24065370"},{"issue":"3","key":"10056_CR66","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s11906-011-0192-0","volume":"13","author":"BS Huang","year":"2011","unstructured":"Huang BS, Leenen FHH. Mineralocorticoid actions in the brain and hypertension. Curr Hypertens Rep. 2011;13(3):214\u201320.","journal-title":"Curr Hypertens Rep"},{"issue":"12","key":"10056_CR67","doi-asserted-by":"publisher","first-page":"4456","DOI":"10.1210\/jc.2018-00866","volume":"103","author":"Y Ohno","year":"2018","unstructured":"Ohno Y, Sone M, Inagaki N, Yamasaki T, Ogawa O, Takeda Y, et al. Obesity as a Key Factor Underlying Idiopathic Hyperaldosteronism. J Clin Endocrinol Metab. 2018;103(12):4456\u201364.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10056_CR68","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s12020-020-02576-y","volume":"72","author":"S Grewal","year":"2021","unstructured":"Grewal S, Fosam A, Chalk L, Deven A, Suzuki M, Correa RR, et al. Insulin sensitivity and pancreatic \u03b2-cell function in patients with primary aldosteronism. Endocrine. 2021;72(1):96\u2013103.","journal-title":"Endocrine"},{"issue":"2","key":"10056_CR69","first-page":"e25032","volume":"83","author":"A Hernandez-Rubio","year":"2026","unstructured":"Hernandez-Rubio A, McNally RJ, Pedr\u00f3s Barnils N, Farukh B, Chowienczyk PJ, Cruickshank JK, et al. Role of Ethnicity and Sex in Hypertension-Mediated Organ Damage in a Dual-Ethnic Cohort of Individuals With Hypertension. Hypertens (Dallas Tex 1979). 2026;83(2):e25032.","journal-title":"Hypertens (Dallas Tex 1979)"},{"issue":"7","key":"10056_CR70","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/j.bbadis.2017.04.004","volume":"1863","author":"E Gonzalez-Sanchez","year":"2017","unstructured":"Gonzalez-Sanchez E, Firrincieli D, Housset C, Chignard N. Expression patterns of nuclear receptors in parenchymal and non-parenchymal mouse liver cells and their modulation in cholestasis. Biochim Biophys acta Mol basis Dis. 2017;1863(7):1699\u2013708.","journal-title":"Biochim Biophys acta Mol basis Dis"},{"issue":"1","key":"10056_CR71","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1186\/s12964-024-01991-2","volume":"22","author":"MM Mohib","year":"2024","unstructured":"Mohib MM, Rabe S, Nolze A, Rooney M, Ain Q, Zipprich A, et al. Eplerenone, a mineralocorticoid receptor inhibitor, reduces cirrhosis associated changes of hepatocyte glucose and lipid metabolism. Cell Commun Signal. 2024;22(1):614.","journal-title":"Cell Commun Signal"},{"issue":"3","key":"10056_CR72","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.taap.2014.08.029","volume":"280","author":"N Queisser","year":"2014","unstructured":"Queisser N, Happ K, Link S, Jahn D, Zimnol A, Geier A, et al. Aldosterone induces fibrosis, oxidative stress and DNA damage in livers of male rats independent of blood pressure changes. Toxicol Appl Pharmacol. 2014;280(3):399\u2013407.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"3","key":"10056_CR73","doi-asserted-by":"publisher","first-page":"R253","DOI":"10.1152\/ajpregu.00316.2021","volume":"322","author":"J Habibi","year":"2022","unstructured":"Habibi J, Chen D, Hulse JL, Whaley-Connell A, Sowers JR, Jia G. Targeting mineralocorticoid receptors in diet-induced hepatic steatosis and insulin resistance. Am J Physiol Regul Integr Comp Physiol. 2022;322(3):R253\u201362.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"6","key":"10056_CR74","doi-asserted-by":"publisher","first-page":"101138","DOI":"10.1016\/j.aohep.2023.101138","volume":"28","author":"MM Ram\u00edrez-Mej\u00eda","year":"2023","unstructured":"Ram\u00edrez-Mej\u00eda MM, Qi X, Abenavoli L, Romero-G\u00f3mez M, Eslam M, M\u00e9ndez-S\u00e1nchez N. Metabolic dysfunction: The silenced connection with fatty liver disease. Ann Hepatol. 2023;28(6):101138.","journal-title":"Ann Hepatol"},{"key":"10056_CR75","doi-asserted-by":"publisher","unstructured":"Li Z, Luo G, Gan C, Zhang H, Li L, Zhang X et al. Spatially resolved multi-omics of human metabolic dysfunction-associated steatotic liver disease. Nat Genet [Internet]. 2025;57(December). Available from: https:\/\/doi.org\/10.1038\/s41588-025-02407-8","DOI":"10.1038\/s41588-025-02407-8"},{"issue":"11","key":"10056_CR76","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1161\/CIRCRESAHA.108.174235","volume":"102","author":"M Caprio","year":"2008","unstructured":"Caprio M, Newfell BG, la Sala A, Baur W, Fabbri A, Rosano G, et al. Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res. 2008;102(11):1359\u201367.","journal-title":"Circ Res"},{"key":"10056_CR77","doi-asserted-by":"crossref","unstructured":"Kirsch T, Beese M, Wyss K, Klinge U, Haller H, Haubitz M et al. Aldosterone modulates endothelial permeability and endothelial nitric oxide synthase activity by rearrangement of the actin cytoskeleton. Hypertens (Dallas, Tex 1979). 2013;61(2):501\u20138.","DOI":"10.1161\/HYPERTENSIONAHA.111.196832"},{"issue":"6","key":"10056_CR78","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.2337\/db16-1354","volume":"66","author":"Y-Y Zhang","year":"2017","unstructured":"Zhang Y-Y, Li C, Yao G-F, Du L-J, Liu Y, Zheng X-J, et al. Deletion of Macrophage Mineralocorticoid Receptor Protects Hepatic Steatosis and Insulin Resistance Through ER\u03b1\/HGF\/Met Pathway. Diabetes. 2017;66(6):1535\u201347.","journal-title":"Diabetes"},{"key":"10056_CR79","doi-asserted-by":"publisher","first-page":"563434","DOI":"10.3389\/fimmu.2020.563434","volume":"11","author":"N Mu\u00f1oz-Durango","year":"2020","unstructured":"Mu\u00f1oz-Durango N, Arrese M, Hern\u00e1ndez A, Jara E, Kalergis AM, Cabrera D. A Mineralocorticoid Receptor Deficiency in Myeloid Cells Reduces Liver Steatosis by Impairing Activation of CD8(+) T Cells in a Nonalcoholic Steatohepatitis Mouse Model. Front Immunol. 2020;11:563434.","journal-title":"Front Immunol"},{"issue":"14","key":"10056_CR80","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1111\/bph.14341","volume":"175","author":"B Schreier","year":"2018","unstructured":"Schreier B, Wolf A, Hammer S, Pohl S, Mildenberger S, Rabe S, et al. The selective mineralocorticoid receptor antagonist eplerenone prevents decompensation of the liver in cirrhosis. Br J Pharmacol. 2018;175(14):2956\u201367.","journal-title":"Br J Pharmacol"},{"issue":"9","key":"10056_CR81","first-page":"2129","volume":"35","author":"M Pizarro","year":"2015","unstructured":"Pizarro M, Sol\u00eds N, Quintero P, Barrera F, Cabrera D, Rojas-de Santiago P, et al. Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis. Liver Int Off J Int Assoc Study Liver. 2015;35(9):2129\u201338.","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"issue":"2","key":"10056_CR82","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0168-8278(00)00087-8","volume":"34","author":"K Rombouts","year":"2001","unstructured":"Rombouts K, Niki T, Wielant A, Hellemans K, Schuppan D, Kormoss N, et al. Effect of aldosterone on collagen steady state levels in primary and subcultured rat hepatic stellate cells. J Hepatol. 2001;34(2):230\u20138.","journal-title":"J Hepatol"},{"issue":"13","key":"10056_CR83","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1111\/bph.15784","volume":"179","author":"B Schreier","year":"2022","unstructured":"Schreier B, Zipprich A, Uhlenhaut H, Gekle M. Mineralocorticoid receptors in non-alcoholic fatty liver disease. Br J Pharmacol. 2022;179(13):3165\u201377.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10056_CR84","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/hep.30252","volume":"69","author":"ME Inzaugarat","year":"2019","unstructured":"Inzaugarat ME, Johnson CD, Holtmann TM, McGeough MD, Trautwein C, Papouchado BG, et al. NLR Family Pyrin Domain-Containing 3 Inflammasome Activation in Hepatic Stellate Cells Induces Liver Fibrosis in Mice. Hepatology. 2019;69(2):845\u201359.","journal-title":"Hepatology"},{"issue":"6","key":"10056_CR85","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1053\/j.gastro.2019.01.010","volume":"156","author":"S Chaturantabut","year":"2019","unstructured":"Chaturantabut S, Shwartz A, Evason KJ, Cox AG, Labella K, Schepers AG, et al. Estrogen Activation of G-Protein-Coupled Estrogen Receptor 1 Regulates Phosphoinositide 3-Kinase and mTOR Signaling to Promote Liver Growth in Zebrafish and Proliferation of Human Hepatocytes. Gastroenterology. 2019;156(6):1788\u2013e180413.","journal-title":"Gastroenterology"},{"issue":"3","key":"10056_CR86","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/hep.26752","volume":"59","author":"AE Zucchetti","year":"2014","unstructured":"Zucchetti AE, Barosso IR, Boaglio AC, Basiglio CL, Miszczuk G, Larocca MC, et al. G-protein-coupled receptor 30\/adenylyl cyclase\/protein kinase A pathway is involved in estradiol 17\u00df-D-glucuronide-induced cholestasis. Hepatology. 2014;59(3):1016\u201329.","journal-title":"Hepatology"},{"issue":"12","key":"10056_CR87","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1158\/1541-7786.MCR-20-0173","volume":"18","author":"G Feng","year":"2020","unstructured":"Feng G, Cai J, Huang Y, Zhu X, Gong B, Yang Z, et al. G-Protein-Coupled Estrogen Receptor 1 Promotes Gender Disparities in Hepatocellular Carcinoma via Modulation of SIN1 and mTOR Complex 2 Activity. Mol Cancer Res. 2020;18(12):1863\u201375.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"10056_CR88","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ajh.2009.206","volume":"23","author":"F Fallo","year":"2010","unstructured":"Fallo F, Dalla Pozza A, Tecchio M, Tona F, Sonino N, Ermani M, et al. Nonalcoholic fatty liver disease in primary aldosteronism: a pilot study. Am J Hypertens. 2010;23(1):2\u20135.","journal-title":"Am J Hypertens"},{"issue":"6","key":"10056_CR89","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/cen.15231","volume":"102","author":"I Tizianel","year":"2025","unstructured":"Tizianel I, Madinelli A, Crim\u00ec F, Barbot M, Censi S, Sabbadin C, et al. Prevalence of Metabolic-Associated Steatotic Liver Disease in Patients With Primary Aldosteronism. Clin Endocrinol (Oxf). 2025;102(6):618\u201325.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10056_CR90","doi-asserted-by":"publisher","first-page":"565714","DOI":"10.3389\/fendo.2021.565714","volume":"12","author":"Y Chen","year":"2021","unstructured":"Chen Y, Chen X, Chen Q, Yu C. Non-Alcoholic Fatty Liver Disease and Hypokalemia in Primary Aldosteronism Among Chinese Population. Front Endocrinol (Lausanne). 2021;12:565714.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10056_CR91","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.clnu.2024.12.011","volume":"44","author":"Q Zeng","year":"2025","unstructured":"Zeng Q, Luo X, Chen X, Luo W, Li R, Yang S, et al. Renin-independent aldosteronism and metabolic dysfunction-associated steatotic liver disease and cirrhosis: A genetic association study. Clin Nutr. 2025;44:193\u2013200.","journal-title":"Clin Nutr"},{"key":"10056_CR92","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.2147\/DMSO.S408722","volume":"16","author":"J Hu","year":"2023","unstructured":"Hu J, Cai X, Zhu Q, Heizhati M, Wen W, Luo Q, et al. Relationship Between Plasma Aldosterone Concentrations and Non-Alcoholic Fatty Liver Disease Diagnosis in Patients with Hypertension: A Retrospective Cohort Study. Diabetes Metab Syndr Obes. 2023;16:1625\u201336.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"5","key":"10056_CR93","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1210\/js.2017-00055","volume":"1","author":"A Kumar","year":"2017","unstructured":"Kumar A, Blackshear C, Subauste JS, Esfandiari NH, Oral EA, Subauste AR. Fatty Liver Disease, Women, and Aldosterone: Finding a Link in the Jackson Heart Study. J Endocr Soc. 2017;1(5):460\u20139.","journal-title":"J Endocr Soc"},{"issue":"9","key":"10056_CR94","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1097\/MEG.0b013e328360554a","volume":"25","author":"A Gamliel-Lazarovich","year":"2013","unstructured":"Gamliel-Lazarovich A, Raz-Pasteur A, Coleman R, Keidar S. The effects of aldosterone on diet-induced fatty liver formation in male C57BL\/6 mice: comparison of adrenalectomy and mineralocorticoid receptor blocker. Eur J Gastroenterol Hepatol. 2013;25(9):1086\u201392.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"10056_CR95","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12876-023-02781-9","volume":"23","author":"A Eshraghian","year":"2023","unstructured":"Eshraghian A, Taghavi A, Nikoupour H, Nikeghbalian S, Malek-Hosseini SA. Angiotensin receptor blockers might be protective against hepatic steatosis after liver transplantation. BMC Gastroenterol. 2023;23(1):152.","journal-title":"BMC Gastroenterol"},{"issue":"2","key":"10056_CR96","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/HEP.0000000000001333","volume":"83","author":"WH Ng","year":"2026","unstructured":"Ng WH, Yeo YH, Kim H, Seki E, Rees J, Ma KS-K, et al. Renin-angiotensin-aldosterone system inhibitor use improves clinical outcomes in patients with metabolic dysfunction-associated steatotic liver diseases: Target trial emulation using real-world data. Hepatology. 2026;83(2):333\u201343.","journal-title":"Hepatology"},{"issue":"1","key":"10056_CR97","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1038\/s41598-021-81959-1","volume":"11","author":"KM Kim","year":"2021","unstructured":"Kim KM, Roh J-H, Lee S, Yoon J-H. Clinical implications of renin-angiotensin system inhibitors for development and progression of non-alcoholic fatty liver disease. Sci Rep. 2021;11(1):2884.","journal-title":"Sci Rep"},{"issue":"9","key":"10056_CR98","doi-asserted-by":"publisher","first-page":"e0163069","DOI":"10.1371\/journal.pone.0163069","volume":"11","author":"S Pelusi","year":"2016","unstructured":"Pelusi S, Petta S, Rosso C, Borroni V, Fracanzani AL, Dongiovanni P, et al. Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease. PLoS ONE. 2016;11(9):e0163069.","journal-title":"PLoS ONE"},{"issue":"9","key":"10056_CR99","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1097\/MEG.0000000000002986","volume":"37","author":"D Shen","year":"2025","unstructured":"Shen D, Song S, Hu J, Cai X, Zhu Q, Zhang Y, et al. The potential of spironolactone to mitigate the risk of nonalcoholic fatty liver disease in hypertensive populations: evidence from a cohort study. Eur J Gastroenterol Hepatol. 2025;37(9):1010\u201320.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"4","key":"10056_CR100","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1177\/1470320311402110","volume":"12","author":"SA Polyzos","year":"2011","unstructured":"Polyzos SA, Kountouras J, Zafeiriadou E, Patsiaoura K, Katsiki E, Deretzi G, et al. Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease. J Renin Angiotensin Aldosterone Syst. 2011;12(4):498\u2013503.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"1","key":"10056_CR101","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/dom.15305","volume":"26","author":"N Perakakis","year":"2024","unstructured":"Perakakis N, Bornstein SR, Birkenfeld AL, Linkermann A, Demir M, Anker SD, et al. Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysis. Diabetes Obes Metab. 2024;26(1):191\u2013200.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10056_CR102","first-page":"797","volume":"38","author":"CS Chaudhury","year":"2018","unstructured":"Chaudhury CS, Purdy JB, Liu C-Y, Morse CG, Stanley TL, Kleiner D, et al. Unanticipated increases in hepatic steatosis among human immunodeficiency virus patients receiving mineralocorticoid receptor antagonist eplerenone for non-alcoholic fatty liver disease. Liver Int Off J Int Assoc Study Liver. 2018;38(5):797\u2013802.","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"issue":"Pt 3","key":"10056_CR103","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1177\/0004563215603401","volume":"53","author":"P O\u2019Shea","year":"2016","unstructured":"O\u2019Shea P, Brady JJ, Gallagher N, Dennedy MC, Fitzgibbon M. Establishment of reference intervals for aldosterone and renin in a Caucasian population using the newly developed Immunodiagnostic Systems specialty immunoassay automated system. Ann Clin Biochem. 2016;53(Pt 3):390\u20138.","journal-title":"Ann Clin Biochem"},{"issue":"5","key":"10056_CR104","doi-asserted-by":"publisher","first-page":"F873","DOI":"10.1152\/ajprenal.00109.2017","volume":"314","author":"TJ Toering","year":"2018","unstructured":"Toering TJ, Gant CM, van der Visser FW, Laverman GD, Danser AHJ, et al. Sex differences in renin-angiotensin-aldosterone system affect extracellular volume in healthy subjects. Am J Physiol Ren Physiol. 2018;314(5):F873\u20138.","journal-title":"Am J Physiol Ren Physiol"},{"issue":"10","key":"10056_CR105","doi-asserted-by":"publisher","first-page":"3981","DOI":"10.1210\/jc.2006-1154","volume":"91","author":"ED Szmuilowicz","year":"2006","unstructured":"Szmuilowicz ED, Adler GK, Williams JS, Green DE, Yao TM, Hopkins PN, et al. Relationship between aldosterone and progesterone in the human menstrual cycle. J Clin Endocrinol Metab. 2006;91(10):3981\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"10056_CR106","doi-asserted-by":"publisher","first-page":"113976","DOI":"10.1016\/j.bcp.2020.113976","volume":"177","author":"ME Baker","year":"2020","unstructured":"Baker ME, Katsu Y, Progesterone. An enigmatic ligand for the mineralocorticoid receptor. Biochem Pharmacol. 2020;177:113976.","journal-title":"Biochem Pharmacol"},{"key":"10056_CR107","doi-asserted-by":"publisher","first-page":"108486","DOI":"10.1016\/j.steroids.2019.108486","volume":"152","author":"GP Rossi","year":"2019","unstructured":"Rossi GP, Caroccia B, Seccia TM. Role of estrogen receptors in modulating aldosterone biosynthesis and blood pressure. Steroids. 2019;152:108486.","journal-title":"Steroids"},{"issue":"5","key":"10056_CR108","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1161\/01.HYP.0000124251.06056.8e","volume":"43","author":"RS Vasan","year":"2004","unstructured":"Vasan RS, Evans JC, Benjamin EJ, Levy D, Larson MG, Sundstrom J, et al. Relations of serum aldosterone to cardiac structure: gender-related differences in the Framingham Heart Study. Hypertens (Dallas Tex 1979). 2004;43(5):957\u201362.","journal-title":"Hypertens (Dallas Tex 1979)"},{"issue":"2","key":"10056_CR109","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1161\/HYPERTENSIONAHA.110.168427","volume":"58","author":"EJ Belin de Chantem\u00e8le","year":"2011","unstructured":"Belin de Chantem\u00e8le EJ, Mintz JD, Rainey WE, Stepp DW. Impact of leptin-mediated sympatho-activation on cardiovascular function in obese mice. Hypertens (Dallas Tex 1979). 2011;58(2):271\u20139.","journal-title":"Hypertens (Dallas Tex 1979)"},{"issue":"3","key":"10056_CR110","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1210\/clinem\/dgae566","volume":"110","author":"GL Hundemer","year":"2025","unstructured":"Hundemer GL, Agharazii M, Madore F, Pich\u00e9 M-E, Gagnon C, Bussi\u00e8res A, et al. Sex-specific Associations of Aldosterone and Renin With Body Composition: A Population-based Cohort Study. J Clin Endocrinol Metab. 2025;110(3):801\u201310.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10056_CR111","doi-asserted-by":"publisher","first-page":"e076444","DOI":"10.1136\/bmjopen-2023-076444","volume":"14","author":"S Bansal","year":"2024","unstructured":"Bansal S, Canziani MEF, Birne R, Anker SD, Bakris GL, Filippatos G, et al. Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials. BMJ Open. 2024;14(3):e076444.","journal-title":"BMJ Open"},{"issue":"9","key":"10056_CR112","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1089\/ars.2021.0044","volume":"35","author":"A Mor\u00e1n-Costoya","year":"2021","unstructured":"Mor\u00e1n-Costoya A, Proenza AM, Gianotti M, Llad\u00f3 I, Valle A. Sex Differences in Nonalcoholic Fatty Liver Disease: Estrogen Influence on the Liver-Adipose Tissue Crosstalk. Antioxid Redox Signal. 2021;35(9):753\u201374.","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"10056_CR113","doi-asserted-by":"publisher","first-page":"e70121","DOI":"10.1002\/dmrr.70121","volume":"42","author":"J Stokar","year":"2026","unstructured":"Stokar J, Dresner-Pollak R. Earlier Menopause and Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Global Cohort Study. Diabetes Metab Res Rev. 2026;42(1):e70121.","journal-title":"Diabetes Metab Res Rev"},{"issue":"2","key":"10056_CR114","first-page":"460","volume":"44","author":"D Kim","year":"2024","unstructured":"Kim D, Manikat R, Cholankeril G, Ahmed A. Endogenous sex hormones and nonalcoholic fatty liver disease in US adults. Liver Int Off J Int Assoc Study Liver. 2024;44(2):460\u201371.","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"issue":"6","key":"10056_CR115","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474\u201384.","journal-title":"Eur Heart J"},{"issue":"1","key":"10056_CR116","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","volume":"75","author":"S Ito","year":"2020","unstructured":"Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M, Yamakawa S. Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study). Hypertens (Dallas Tex 1979). 2020;75(1):51\u20138.","journal-title":"Hypertens (Dallas Tex 1979)"},{"issue":"1","key":"10056_CR117","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1161\/HYPERTENSIONAHA.120.15199","volume":"76","author":"G Bakris","year":"2020","unstructured":"Bakris G, Yang YF, Pitt B. Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease: BLOCK-CKD Trial. Hypertens (Dallas Tex 1979). 2020;76(1):144\u20139.","journal-title":"Hypertens (Dallas Tex 1979)"},{"issue":"5","key":"10056_CR118","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2213169","volume":"388","author":"MW Freeman","year":"2023","unstructured":"Freeman MW, Halvorsen Y-D, Marshall W, Pater M, Isaacsohn J, Pearce C, et al. Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. N Engl J Med. 2023;388(5):395\u2013405.","journal-title":"N Engl J Med"},{"issue":"5","key":"10056_CR119","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1001\/jama.2025.9413","volume":"334","author":"M Saxena","year":"2025","unstructured":"Saxena M, Laffin L, Borghi C, Fernandez Fernandez B, Ghali JK, Kopjar B, et al. Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical Trial. JAMA. 2025;334(5):409\u201318.","journal-title":"JAMA"},{"key":"10056_CR120","doi-asserted-by":"publisher","first-page":"102576","DOI":"10.1016\/j.eclinm.2024.102576","volume":"71","author":"P Mulatero","year":"2024","unstructured":"Mulatero P, Wuerzner G, Groessl M, Sconfienza E, Damianaki A, Forestiero V, et al. Safety and efficacy of once-daily dexfadrostat phosphate in patients with primary aldosteronism: a randomised, parallel group, multicentre, phase 2 trial. EClinicalMedicine. 2024;71:102576.","journal-title":"EClinicalMedicine"},{"issue":"7","key":"10056_CR121","doi-asserted-by":"publisher","first-page":"9083","DOI":"10.1007\/s00210-025-03838-0","volume":"398","author":"F Schulze","year":"2025","unstructured":"Schulze F, Schaible J, Goettel M, Tanaka Y, Hohl K, Schultz A, et al. Phase 1 studies of the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 690517 (vicadrostat), a novel aldosterone synthase inhibitor, in healthy male volunteers. Naunyn Schmiedebergs Arch Pharmacol. 2025;398(7):9083\u201398.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-026-10056-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11154-026-10056-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-026-10056-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:02:31Z","timestamp":1790442151000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11154-026-10056-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":121,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10056"],"URL":"https:\/\/doi.org\/10.1007\/s11154-026-10056-3","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"24 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}]}}